2n0i
From Proteopedia
(Difference between revisions)
| Line 8: | Line 8: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2n0i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2n0i OCA], [https://pdbe.org/2n0i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2n0i RCSB], [https://www.ebi.ac.uk/pdbsum/2n0i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2n0i ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2n0i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2n0i OCA], [https://pdbe.org/2n0i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2n0i RCSB], [https://www.ebi.ac.uk/pdbsum/2n0i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2n0i ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| - | <div style="background-color:#fffaf0;"> | ||
| - | == Publication Abstract from PubMed == | ||
| - | Cyclic constraints are incorporated here into an 11-residue analogue of the N-terminus of glucagon-like peptide-1 (GLP-1) to investigate effects of structure on agonist activity. Cyclization through linking side chains of residues 2 and 5 or 5 and 9 produced agonists at nM concentrations in a cAMP assay. 2D-NMR and CD spectra revealed an N-terminal beta-turn and a C-terminal helix that differentially influenced affinity and agonist potency. These structures can inform development of small molecule agonists of the GLP-1 receptor to treat type 2 diabetes. | ||
| - | |||
| - | Short hydrophobic peptides with cyclic constraints are potent glucagon-like peptide-1 receptor (GLP-1R) agonists.,Hoang HN, Song K, Hill TA, Derksen DR, Edmonds DJ, Kok WM, Limberakis C, Liras S, Loria PM, Mascitti V, Mathiowetz AM, Mitchell JM, Piotrowski DW, Price DA, Stanton RV, Suen JY, Withka JM, Griffith DA, Fairlie DP J Med Chem. 2015 Apr 3. PMID:25839426<ref>PMID:25839426</ref> | ||
| - | |||
| - | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| - | </div> | ||
| - | <div class="pdbe-citations 2n0i" style="background-color:#fffaf0;"></div> | ||
| - | == References == | ||
| - | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
Revision as of 06:28, 3 April 2024
NMR solution structure for di-sulfide 11mer peptide
| |||||||||||
Categories: Large Structures | Derksen DR | Edmonds DJ | Fairlie DP | Griffith DA | Hill TA | Hoang HN | Kok WM | Limberakis C | Liras S | Loria PM | Mascitti V | Mathiowetz AM | Mitchell JM | Piotrowski DW | Price DA | Song K | Stanton RV | Suen JY | Withka JM
